medicare coverage of glp 1 drugs GLP-1 Medical Coding GLP-1 Medications |
Description
Cell Physiol Biochem (2017) 44(5):1696714
Metabolic changes In a double-blind, placebo-controlled RCT conducted by Frssing et al
Annals of Surgery
This reduction occurs gradually over 612 months and appears to be sustained with continued treatment
Notably, considerable metabolic improvement was achieved at relatively low doses of GLP1/E, thus increasing the safety margin of this compound, which did not cause uterotrophic effects per se
There is growing interest in exploring GLP-1 medications as promising adjunct therapies to insulin for individuals with T1D
